Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

The recent FDA thumbs-up for Beyfortus could kickstart a new chapter in RSV prevention

By Brian Buntz | July 17, 2023

BeyfortusRespiratory syncytial virus (RSV) is a common cause of severe lower respiratory tract infections like pneumonia and bronchiolitis in infants and young children. Traditionally there have been no approved treatments for RSV infections, with care being largely supportive. But the landscape is quickly changing.

The FDA recently approved Beyfortus (nirsevimab), the first immunoprophylactic to prevent RSV disease in newborns, infants and toddlers. On the RSV vaccine front, FDA also approved GSK‘s (NYSE:GSK) Arexvy. Other RSV vaccine candidates are waiting in the wings.

A shift in the RSV treatment landscape

Beyfortus is a monoclonal antibody developed by AstraZeneca and Sanofi that provides protection against RSV with a single intramuscular injection. It is the first innovation in RSV prevention in over two decades. Until recently, the only preventive therapy on the market was Synagis, a monoclonal antibody used to help prevent serious lung disease from RSV in high-risk infants and young children. The drug, developed by MedImmune (eventually acquired by AstraZeneca), now belongs to Sobi.

With Beyfortus’ arrival, the RSV prophylaxis landscape could shift significantly. The drug represents the first major innovation in more than 20 years for preventing RSV infections in infants. It is also the first RSV preventive therapy designed to protect a broad population of infants, including those born healthy at term, preterm or with certain health conditions that increase their risk of severe RSV disease. With its recent approval in the U.S. and E.U., and regulatory reviews underway in other countries like China and Japan, Beyfortus is set to transform RSV prevention globally.

Clinical trials and safety

Three clinical trials demonstrated Beyfortus’ ability to significantly reduce medically-attended RSV lower respiratory tract infections compared to placebo in both preterm and term infants. Clinical data also shows it to be effective in children up to 24 months old who remain vulnerable to severe RSV disease. Potential side effects include rash and injection site reactions.

The recent FDA approval of Beyfortus was based on data from three late-stage clinical trials showing a favorable benefit-risk profile, leading to a unanimous recommendation for approval by the Antimicrobial Drugs Advisory Committee.

The FDA granted Fast Track designation to expedite Beyfortus’ development and regulatory review.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE